Aadi Bioscience to Present at Upcoming Investor Conferences

Rhea-AI Summary

Aadi Bioscience, a biopharmaceutical company focused on precision therapies for genetically defined cancers, will present at three major conferences in November 2022. These include the H.C. Wainwright Precision Oncology Virtual Conference on November 14, the Jefferies London Healthcare Conference from November 15-17, and the Piper Sandler Healthcare Conference from November 29 to December 1. CEO Neil Desai and COO Brendan Delaney will engage in discussions highlighting the company's advancements, including the FDA-approved FYARRO® treatment for certain cancer patients.

LOS ANGELES, Nov. 3, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that the Company will be presenting and hosting one-on-one meetings at the following conferences during November:

• H.C. Wainwright 3^rd Annual Precision Oncology Virtual Conference, November 14, 2022
• Neil Desai, Ph.D., Aadi Bioscience Founder and CEO, will participate in a fireside chat with the banking equity analyst, available on demand to registered conference attendees
  
  
• Jefferies London Healthcare Conference, November 15-17, 2022, in London
• Neil Desai, Ph.D., Aadi Bioscience Founder and CEO, and Brendan Delaney, Aadi Bioscience COO, will take part in a hybrid presentation including a moderated Q&A session on Tuesday, November 15^th, at 3:35 am ET (8:35 am GMT)
  
  
• Piper Sandler 34^th Annual Healthcare Conference, November 29-December 1, 2022, in New York
• Dr. Desai and Mr. Delaney will participate in a fireside chat with the equity analyst on Wednesday, November 30, 2022 at 12:30 pm ET

Replays of webcasts will be available on IR pages of the Aadi Biosciences website for approximately 30 days following each presentation.

About Aadi Bioscience, Inc.

Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Aadi received FDA approval in November of 2021 and in February of 2022 commercialized FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi has also initiated PRECISION 1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on the Company's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:
Marcy Graham
IR@aadibio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-present-at-upcoming-investor-conferences-301667554.html

SOURCE Aadi Bioscience

FAQ

What are the key events for Aadi Bioscience in November 2022?

Aadi Bioscience will present at three conferences: H.C. Wainwright Precision Oncology Conference on November 14, Jefferies London Healthcare Conference from November 15-17, and Piper Sandler Healthcare Conference from November 29 to December 1.

Who will represent Aadi Bioscience at the conferences?

CEO Neil Desai and COO Brendan Delaney will represent Aadi Bioscience at the conferences.

What is the focus of Aadi Bioscience's presentations?

Aadi Bioscience's presentations will focus on precision therapies for genetically defined cancers and their FDA-approved treatment, FYARRO®.

When is Aadi Bioscience's fireside chat at the Jefferies London Healthcare Conference?

The fireside chat will take place on November 15 at 3:35 am ET (8:35 am GMT).

How can I access Aadi Bioscience's presentation replays?

Replays of the presentations will be available on the Investor Relations page of Aadi Bioscience's website for approximately 30 days following each event.